Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

Owen A. O'Connor, Carol Portlock, Craig Moskowitz, Paul Hamlin, David Straus, John Gerecitano, Mithat Gonen, Otilia Dumitrescu, Debra Sarasohn, John Butos, Ellen Neylon, Barbara Mac Gregor Cortelli, Susan Blumel, Andrew M. Evens, Andrew D. Zelenetz, John Wright, Brenda Cooper, Jane Winter, Julie Vose

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Purpose: To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma. Experimental Design: Patients with follicular lymphoma (FL), marginal zone lymphoma, mantle cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia were eligible for study. Bortezomib was given at a dose of 1.5 mg/m2 as an i.v. push on days 1, 4, 8, and 11 of a 21-day cycle. Eligibility included the following: (a) no more than three prior therapies, (b) at least 1 month since prior chemotherapy, (c) measurable disease, and (d) an absolute neutrophil count of >1,000/μL and a platelet count >50,000/μL for the first dose of any cycle. Results: Seventy-seven patients were registered, of which 69 were assessable for response based on the completion of two cycles of therapy. Subtypes included FL (59.5%), mantle cell lymphoma (52%), small lymphocytic lymphoma/chronic lymphocytic leukemia (16.2%), marginal zone lymphoma (21.6%), and one Waldenstrom's macroglobulinemia. The median number of prior therapies was three. Themost common grade 3 toxicity was lymphopenia (35%) and thrombocytopenia (31%). Twenty-five patients experienced grade ≤2 sensory neuropathy (32), and 8% experienced grade 3 neurosensory toxicity. The overall response rate was 45% (40% on an intention to treat) including 10 complete remissions. Of 18 patients with FL, 9 responded with 4 complete response. The median time to treatment response for FL was 12 weeks, whereas the median time to treatment response for other subtypes of non-Hodgkin's lymphoma was only 4 weeks. Conclusions: These data suggest that bortezomib has significant single agent activity in patients with FL, and that longer durations of treatment may improve overall response.

Original languageEnglish (US)
Pages (from-to)719-726
Number of pages8
JournalClinical Cancer Research
Volume16
Issue number2
DOIs
StatePublished - Jan 15 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes'. Together they form a unique fingerprint.

  • Cite this

    O'Connor, O. A., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Gerecitano, J., Gonen, M., Dumitrescu, O., Sarasohn, D., Butos, J., Neylon, E., Cortelli, B. M. G., Blumel, S., Evens, A. M., Zelenetz, A. D., Wright, J., Cooper, B., Winter, J., & Vose, J. (2010). Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical Cancer Research, 16(2), 719-726. https://doi.org/10.1158/1078-0432.CCR-08-2647